![]() In addition, it offers DoseMeRx, a decision support software that leverages clinically validated pharmacokinetic drug models, patient characteristics, drug concentrations, and genotypes to guide dose optimization and PrescribeWellness, a PrescribeWellness, a patient engagement center platform. The company also provides TruChart that offers electronic health records (EHR), care coordination, and financial management in one program allowing Programs of All-Inclusive Care for the Elderly (PACE) to track measurable outcomes in defined timeframes for the populations they serve and PACElogic, which delivers sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state that requires reporting. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. operates as a healthcare technology company in the United States. To read this article on click here.Tabula Rasa HealthCare, Inc. Tabula Rasa Healthcare (TRHC) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Strata Skin Sciences, Inc.'s revenues are expected to be $8.46 million, up 9.7% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This company is expected to post quarterly loss of $0.06 per share in its upcoming report, which represents a year-over-year change of -200%. The results are expected to be released on November 9. (SSKN), another stock in the same industry, has yet to report results for the quarter ended September 2022. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 29% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Tabula Rasa Healthcare has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Tabula Rasa Healthcare shares have lost about 75.5% since the beginning of the year versus the S&P 500's decline of -21.1%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. The company has topped consensus revenue estimates two times over the last four quarters. This compares to year-ago revenues of $86.59 million. Tabula Rasa Healthcare, which belongs to the Zacks Medical Info Systems industry, posted revenues of $77.1 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 4.64%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. A quarter ago, it was expected that this developer of health care software would post earnings of $0.01 per share when it actually produced a loss of $0.32, delivering a surprise of -3,300%. This quarterly report represents an earnings surprise of -1,366.67%. These figures are adjusted for non-recurring items. ![]() This compares to loss of $0.04 per share a year ago. Tabula Rasa Healthcare (TRHC) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.03.
0 Comments
Leave a Reply. |